{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:06:45Z","timestamp":1792174005531,"version":"4.4.0"},"reference-count":245,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04385-1","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:04:15Z","timestamp":1781593455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches"],"prefix":"10.1186","volume":"26","author":[{"given":"Mahdi","family":"Jafarlou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Jafarlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Azimzadeh","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Ghorbaninezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Shakiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"1","key":"4385_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-025-01257-1","volume":"56","author":"JX Nie","year":"2025","unstructured":"Nie JX, et al. Rising Incidence of Total and Early-Onset Colorectal Cancer: A Global Perspective on Burden, Risk Factors, and Projections to 2031. J Gastrointest Cancer. 2025;56(1):138.","journal-title":"J Gastrointest Cancer"},{"key":"4385_CR2","unstructured":"Siegel RA-O et al. Cancer statistics, 2025. (1542\u20134863 (Electronic))."},{"key":"4385_CR3","unstructured":"Bretthauer M et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. (1533\u20134406 (Electronic))."},{"key":"4385_CR4","unstructured":"Oh JM et al. Compr Rev Resist Mech colorectal cancer classified therapy type (1664\u20133224 (Electronic))."},{"issue":"3","key":"4385_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1134\/S1062359022150109","volume":"49","author":"H Khalil","year":"2022","unstructured":"Khalil H, et al. The Effects of siRNA-Mediated Gene Silencing of Alpha-7 Nicotinic Acetylcholine Receptors on Drug Resistance to Oxaliplatin in Colorectal Cancer Cells. Biology Bull. 2022;49(3):S1\u20138.","journal-title":"Biology Bull"},{"key":"4385_CR6","unstructured":"Food US, Drug A. FDA grants accelerated approval to pembrolizumab for first tissue\/site-agnostic indication. 2017; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication"},{"key":"4385_CR7","unstructured":"Graham L, Pritchard, Schweizer MT. Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. (1557\u20133265 (Electronic))."},{"key":"4385_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104775","volume":"212","author":"E Chen","year":"2025","unstructured":"Chen E, Zhou W. Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance. Crit Rev Oncol Hematol. 2025;212:104775.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4385_CR9","volume":"33","author":"H Abushukair","year":"2022","unstructured":"Abushukair H, et al. Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance. Cancer Treat Res Commun. 2022;33:100643.","journal-title":"Cancer Treat Res Commun"},{"issue":"5","key":"4385_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"key":"4385_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016646","volume":"13","author":"J Shan","year":"2022","unstructured":"Shan J, et al. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol. 2022;13:1016646.","journal-title":"Front Immunol"},{"key":"4385_CR12","unstructured":"Kadoch C et al. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. (1546\u2013718 (Electronic))."},{"key":"4385_CR13","unstructured":"Sharma P et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. (1097\u20134172 (Electronic))."},{"key":"4385_CR14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-030617-050606","author":"S Spranger","year":"2018","unstructured":"Spranger S, Gajewski T. Mechanisms of tumor cell\u2014intrinsic immune evasion. Annual Review of Cancer Biology. 2018. https:\/\/doi.org\/10.1146\/annurev-cancerbio-030617-050606.","journal-title":"Annual Review of Cancer Biology"},{"key":"4385_CR15","unstructured":"Huang R et al. Recent advances in CAR-T cell engineering. (1756\u20138722 (Electronic))."},{"key":"4385_CR16","unstructured":"Batlle E, Massagu\u00e9 J. Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer. (1097\u20134180 (Electronic))."},{"key":"4385_CR17","unstructured":"Leone RA-O, Powell JD. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy. (2326\u20136074 (Electronic))."},{"key":"4385_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1713382","volume":"16","author":"CT Jani","year":"2025","unstructured":"Jani CT, et al. Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy. Front Immunol. 2025;16:1713382.","journal-title":"Front Immunol"},{"key":"4385_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1780865","volume":"17","author":"H Chen","year":"2026","unstructured":"Chen H, et al. Gut microbial metabolites in inflammatory bowel disease: immunological mechanisms regulating Treg\/Th17 balance and therapeutic potential. Front Immunol. 2026;17:1780865.","journal-title":"Front Immunol"},{"key":"4385_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.02.003","author":"J Babdor","year":"2026","unstructured":"Babdor J, et al. Immune-microbiome coordination defines interferon setpoints in healthy humans. Cell. 2026. https:\/\/doi.org\/10.1016\/j.cell.2026.02.003.","journal-title":"Cell"},{"key":"4385_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/or.2025.1581856","volume":"19","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, et al. Prospects of engineered bacteria-assisted CAR T Cell therapy in gastrointestinal cancers. Oncol Rev. 2025;19:1581856.","journal-title":"Oncol Rev"},{"issue":"7","key":"4385_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13070689","volume":"13","author":"P Muthukutty","year":"2025","unstructured":"Muthukutty P, Woo HY, Yoo SY. Therapeutic colorectal cancer vaccines: emerging modalities and translational opportunities. Vaccines (Basel). 2025;13(7):689.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"4385_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ijc.33793","volume":"150","author":"KT Lynch","year":"2022","unstructured":"Lynch KT, et al. A pilot trial of vaccination with Carcinoembryonic antigen and Her2\/neu peptides in advanced colorectal cancer. Int J Cancer. 2022;150(1):164\u201373.","journal-title":"Int J Cancer"},{"issue":"1","key":"4385_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3892\/ijmm.2025.5545","volume":"56","author":"MH Sultan","year":"2025","unstructured":"Sultan MH, et al. Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment. Int J Mol Med. 2025;56(1):104.","journal-title":"Int J Mol Med"},{"key":"4385_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104629","volume":"208","author":"Y Chang","year":"2025","unstructured":"Chang Y, et al. Combining gut microbiota modulation and immunotherapy: A promising approach for treating microsatellite stable colorectal cancer. Crit Rev Oncol Hematol. 2025;208:104629.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4385_CR26","unstructured":"Veen T et al. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer. (1432\u2009\u2013\u20090851 (Electronic))."},{"key":"4385_CR27","unstructured":"Sahin IH, Saridogan T, Kim R. Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review. (1750\u20137448 (Electronic))."},{"key":"4385_CR28","unstructured":"Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. (0309\u2009\u2013\u20090167 (Print))."},{"key":"4385_CR29","unstructured":"Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. (1525\u20131578 (Print))."},{"key":"4385_CR30","doi-asserted-by":"publisher","unstructured":"De Sousa E Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614-618. https:\/\/doi.org\/10.1038\/nm.3174.","DOI":"10.1038\/nm.3174"},{"key":"4385_CR31","doi-asserted-by":"publisher","unstructured":"Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619-625. https:\/\/doi.org\/10.1038\/nm.3175.","DOI":"10.1038\/nm.3175"},{"key":"4385_CR32","unstructured":"Marisa L et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. (1549\u20131676 (Electronic))."},{"key":"4385_CR33","unstructured":"Roepman P et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. (1097\u2009\u2013\u20090215 (Electronic))."},{"key":"4385_CR34","doi-asserted-by":"publisher","unstructured":"Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356. https:\/\/doi.org\/10.1038\/nm.3967.","DOI":"10.1038\/nm.3967"},{"key":"4385_CR35","doi-asserted-by":"publisher","unstructured":"Stintzing S, Wirapati P, Lenz HJ, et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol. 2019;30(11):1796-1803. https:\/\/doi.org\/10.1093\/annonc\/mdz387.","DOI":"10.1093\/annonc\/mdz387"},{"key":"4385_CR36","unstructured":"Chalmers ZR et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. (1756-994X (Electronic))."},{"key":"4385_CR37","unstructured":"W\u0142odarczyk M et al. Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer. (1873\u20135592 (Electronic))."},{"key":"4385_CR38","unstructured":"Posch F et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. (2162\u20134011 (Print))."},{"key":"4385_CR39","doi-asserted-by":"publisher","unstructured":"Becht E, de Reyni\u00e8s A, Giraldo NA, et al. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clin Cancer Res. 2016;22(16):4057-4066. https:\/\/doi.org\/10.1158\/1078-0432.","DOI":"10.1158\/1078-0432"},{"key":"4385_CR40","unstructured":"Karpinski P, Rossowska J, Sasiadek MM. Immunological Landsc consensus clusters colorectal cancer (1949\u20132553 (Electronic))."},{"issue":"6","key":"4385_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2174\/1566524022666220610094716","volume":"23","author":"S Ghahremani Dehbokri","year":"2023","unstructured":"Ghahremani Dehbokri S, et al. CTLA-4: as an immunosuppressive immune checkpoint in breast cancer. Curr Mol Med. 2023;23(6):521\u20136.","journal-title":"Curr Mol Med"},{"key":"4385_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116416","volume":"173","author":"E Faghfuri","year":"2024","unstructured":"Faghfuri E, Gholizadeh P. The role of Akkermansia muciniphila in colorectal cancer: a double-edged sword of treatment or disease progression? Biomedicine & Pharmacotherapy. 2024;173:116416.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"4385_CR43","unstructured":"Galluzzi LA-O et al. Immunostimulation Chemother era immune Checkp inhibitors (1759\u20134782 (Electronic))."},{"issue":"4","key":"4385_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jnci\/djab106","volume":"114","author":"S ten Hoorn","year":"2022","unstructured":"ten Hoorn S, et al. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis. JNCI J Natl Cancer Inst. 2022;114(4):503\u201316.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4385_CR45","unstructured":"Lal N et al. An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. (2162\u20134011 (Print))."},{"key":"4385_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1532924","author":"J Zhang","year":"2025","unstructured":"Zhang J, et al. Prognostic and predictive molecular biomarkers in colorectal cancer. Frontiers in Oncology. 2025. https:\/\/doi.org\/10.3389\/fonc.2025.1532924.","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"4385_CR47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ijc.34464","volume":"153","author":"Q Wang","year":"2023","unstructured":"Wang Q, et al. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. Int J Cancer. 2023;153(4):709\u201322.","journal-title":"Int J Cancer"},{"issue":"1","key":"4385_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-025-00811-2","volume":"11","author":"H Zhang","year":"2025","unstructured":"Zhang H, et al. Spatially resolved C1QC+ macrophage-CD4\u2009+\u2009T cell niche in colorectal cancer microenvironment: implications for immunotherapy response. Cell Discov. 2025;11(1):60.","journal-title":"Cell Discov"},{"key":"4385_CR49","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zheng J. Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv Exp Med Biol. 2020;1248:201-226. https:\/\/doi.org\/10.1007\/978-981-15-3266-5_9.","DOI":"10.1007\/978-981-15-3266-5_9"},{"issue":"1","key":"4385_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.34172\/ia.2023.06","volume":"3","author":"N Alizadeh","year":"2023","unstructured":"Alizadeh N, et al. The combination of PD-L1 and CTLA-4 suppression significantly decreased the expression levels of cancer stem cell factors in the pancreatic cancer cell line. ImmunoAnalysis. 2023;3(1):6\u20136.","journal-title":"ImmunoAnalysis"},{"issue":"1","key":"4385_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):320.","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"4385_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910389","volume":"22","author":"N Hosseinkhani","year":"2021","unstructured":"Hosseinkhani N, et al. A systematic review and meta-analysis on the significance of TIGIT in solid cancers: Dual TIGIT\/PD-1 blockade to overcome immune-resistance in solid cancers. Int J Mol Sci. 2021;22(19):10389.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4385_CR53","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s11912-024-01583-w","volume":"26","author":"MA Hamid","year":"2024","unstructured":"Hamid MA, et al. Immunotherapy for microsatellite-stable metastatic colorectal cancer: can we close the gap between potential and practice? Curr Oncol Rep. 2024;26(10):1258\u201370.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"4385_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030863","volume":"15","author":"M San-Roman-Gil","year":"2023","unstructured":"San-Roman-Gil M, et al. Current landscape and potential challenges of immune checkpoint inhibitors in microsatellite stable metastatic colorectal carcinoma. Cancers (Basel). 2023;15(3):863.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4385_CR55","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair\u2013deficient\/microsatellite instability\u2013high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773\u20139.","journal-title":"J Clin Oncol"},{"key":"4385_CR56","doi-asserted-by":"crossref","unstructured":"Hussain FHN, Raza A. Immune checkpoint inhibitors in cancer immunotherapy. In: Critical Developments in Cancer Immunotherapy. IGI Global; 2024. p. 123\u201356.","DOI":"10.4018\/979-8-3693-3976-3.ch004"},{"issue":"3","key":"4385_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030335","volume":"15","author":"P Pandey","year":"2022","unstructured":"Pandey P, et al. Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals (Basel). 2022;15(3):335.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"4385_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27113545","volume":"27","author":"B Amir Taghavi","year":"2022","unstructured":"Amir Taghavi B, et al. Targeted therapy of B7 family checkpoints as an innovative approach to overcome cancer therapy resistance: A review from chemotherapy to immunotherapy. Molecules. 2022;27(11):3545.","journal-title":"Molecules"},{"issue":"26","key":"4385_CR59","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"4385_CR60","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/cells12020258","volume":"12","author":"I Yu","year":"2023","unstructured":"Yu I, Dakwar A, Takabe K. Immunotherapy: recent advances and its future as a neoadjuvant, adjuvant, and primary treatment in colorectal cancer. Cells. 2023;12(2):258.","journal-title":"Cells"},{"key":"4385_CR61","doi-asserted-by":"publisher","first-page":"103147","DOI":"10.1016\/j.critrevonc.2020.103147","volume":"157","author":"PG Alexander","year":"2021","unstructured":"Alexander PG, McMillan DC, Park JH. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. Crit Rev Oncol\/Hematol. 2021;157:103147.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"4385_CR62","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105862","author":"X Wang","year":"2016","unstructured":"Wang X, et al. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther. 2016. https:\/\/doi.org\/10.2147\/OTT.S105862.","journal-title":"OncoTargets Ther"},{"issue":"3","key":"4385_CR63","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/term.1686","volume":"10","author":"S Na","year":"2016","unstructured":"Na S, et al. Regeneration of dental pulp\/dentine complex with a three-dimensional and scaffold\u2010free stem\u2010cell sheet\u2010derived pellet. J Tissue Eng Regen Med. 2016;10(3):261\u201370.","journal-title":"J Tissue Eng Regen Med"},{"issue":"6522","key":"4385_CR64","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020;370(6522):1328\u201334.","journal-title":"Science"},{"issue":"7","key":"4385_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071543","volume":"12","author":"LN Jurado-Priego","year":"2024","unstructured":"Jurado-Priego LN, et al. Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies. Biomedicines. 2024;12(7):1543.","journal-title":"Biomedicines"},{"issue":"14","key":"4385_CR66","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.7150\/thno.21471","volume":"7","author":"Y-P Chen","year":"2017","unstructured":"Chen Y-P, et al. Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications. Theranostics. 2017;7(14):3585.","journal-title":"Theranostics"},{"issue":"2","key":"4385_CR67","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","volume":"8","author":"T Maruhashi","year":"2020","unstructured":"Maruhashi T, et al. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2):e001014.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4385_CR68","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i7.106723","volume":"17","author":"M-Y Chen","year":"2025","unstructured":"Chen M-Y, et al. Adoptive cell therapy in colorectal cancer: advances in chimeric antigen receptor T cells. World Journal of Gastrointestinal Oncology. 2025;17(7):106723.","journal-title":"World Journal of Gastrointestinal Oncology"},{"key":"4385_CR69","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.3389\/fimmu.2018.02940","volume":"9","author":"E Breman","year":"2018","unstructured":"Breman E, et al. Overcoming target driven fratricide for T cell therapy. Front Immunol. 2018;9:2940.","journal-title":"Front Immunol"},{"issue":"23","key":"4385_CR70","doi-asserted-by":"publisher","first-page":"12507","DOI":"10.3390\/ijms252312507","volume":"25","author":"SG Duta-Ion","year":"2024","unstructured":"Duta-Ion SG, et al. Redefining therapeutic approaches in colorectal cancer: targeting molecular pathways and overcoming resistance. Int J Mol Sci. 2024;25(23):12507.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4385_CR71","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/14712598.2021.1933940","volume":"21","author":"C Wang","year":"2021","unstructured":"Wang C, Fakih M. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner? Expert Opin Biol Ther. 2021;21(10):1347\u201357.","journal-title":"Expert Opin Biol Ther"},{"issue":"48","key":"4385_CR72","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.3748\/wjg.v24.i48.5418","volume":"24","author":"S Wagner","year":"2018","unstructured":"Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. World J Gastroenterol. 2018;24(48):5418.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"4385_CR73","doi-asserted-by":"publisher","first-page":"e1461","DOI":"10.1002\/ctm2.1461","volume":"13","author":"YJ Zhu","year":"2023","unstructured":"Zhu YJ, et al. Personalised neoantigen-based therapy in colorectal cancer. Clin Translational Med. 2023;13(11):e1461.","journal-title":"Clin Translational Med"},{"issue":"8","key":"4385_CR74","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","volume":"12","author":"C Zhang","year":"2016","unstructured":"Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. Hum vaccines immunotherapeutics. 2016;12(8):2064\u201374.","journal-title":"Hum vaccines immunotherapeutics"},{"issue":"2","key":"4385_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189281","volume":"1880","author":"F Ghorbaninezhad","year":"2025","unstructured":"Ghorbaninezhad F, et al. The tumor microenvironment and dendritic cells: developers of pioneering strategies in colorectal cancer immunotherapy? Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2025;1880(2):189281.","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer"},{"issue":"6371","key":"4385_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"issue":"10","key":"4385_CR77","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/s41590-024-01925-7","volume":"25","author":"L Santollani","year":"2024","unstructured":"Santollani L, et al. Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity. Nat Immunol. 2024;25(10):1820\u20139.","journal-title":"Nat Immunol"},{"issue":"1","key":"4385_CR78","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication Signal. 2022;20(1):44.","journal-title":"Cell Communication Signal"},{"key":"4385_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041022","author":"N Mulet-Margalef","year":"2023","unstructured":"Mulet-Margalef N, Linares J, Badia-Ramentol J, et al. Challenges and Therapeutic Opportunities in the dMMR\/MSI-H Colorectal Cancer Landscape. Cancers (Basel). 2023;15(4):1022. https:\/\/doi.org\/10.3390\/cancers15041022.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4385_CR80","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36(3):277\u201384.","journal-title":"Ann Oncol"},{"issue":"4","key":"4385_CR81","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4385_CR82","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J experimental Clin cancer Res. 2019;38(1):255.","journal-title":"J experimental Clin cancer Res"},{"key":"4385_CR83","doi-asserted-by":"publisher","first-page":"1440830","DOI":"10.3389\/fimmu.2024.1440830","volume":"15","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yu M, Zhang S. The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies. Front Immunol. 2025;15:1440830.","journal-title":"Front Immunol"},{"issue":"6","key":"4385_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100639","volume":"7","author":"E Garralda","year":"2022","unstructured":"Garralda E, et al. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO open. 2022;7(6):100639.","journal-title":"ESMO open"},{"issue":"5","key":"4385_CR85","doi-asserted-by":"publisher","first-page":"e008689","DOI":"10.1136\/jitc-2023-008689","volume":"12","author":"MJ Overman","year":"2024","unstructured":"Overman MJ, et al. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Immunother Cancer. 2024;12(5):e008689.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4385_CR86","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jcyt.2023.01.009","volume":"25","author":"HC Albrecht","year":"2023","unstructured":"Albrecht HC, et al. Generation of colon cancer-derived tumor-infiltrating T cells (TILs) for adoptive cell therapy. Cytotherapy. 2023;25(5):537\u201347.","journal-title":"Cytotherapy"},{"key":"4385_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557906","volume":"16","author":"C Liu","year":"2025","unstructured":"Liu C, et al. Adoptive immune cell therapy for colorectal cancer. Frontiers in Immunology. 2025;16:1557906.","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"4385_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111854","volume":"17","author":"F P\u00e9rez-Dom\u00ednguez","year":"2025","unstructured":"P\u00e9rez-Dom\u00ednguez F, et al. Oncolytic viruses as a novel therapeutic approach for colorectal cancer: mechanisms, current advances, and future directions. Cancers. 2025;17(11):1854.","journal-title":"Cancers"},{"issue":"10","key":"4385_CR89","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, et al. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"key":"4385_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.904137","volume":"13","author":"X Qin","year":"2022","unstructured":"Qin X, et al. Recent advances in CAR-T cells therapy for colorectal cancer. Frontiers in Immunology. 2022;13:904137.","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"4385_CR91","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s43018-025-00948-9","volume":"6","author":"R Blanco-Dom\u00ednguez","year":"2025","unstructured":"Blanco-Dom\u00ednguez R, et al. Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer. Nat Cancer. 2025;6(6):1056\u201372.","journal-title":"Nat Cancer"},{"issue":"3","key":"4385_CR92","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/ijtm5030033","volume":"5","author":"CR Lewis","year":"2025","unstructured":"Lewis CR, et al. Current and Future Directions in Immunotherapy for Gastrointestinal Malignancies. Int J Translational Med. 2025;5(3):33.","journal-title":"Int J Translational Med"},{"issue":"1","key":"4385_CR93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, et al. Engineering car-t cells. Biomark Res. 2017;5(1):22.","journal-title":"Biomark Res"},{"issue":"23","key":"4385_CR94","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.3390\/cancers13236067","volume":"13","author":"E De Bousser","year":"2021","unstructured":"De Bousser E, Callewaert N, Festjens N. T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy. Cancers. 2021;13(23):6067.","journal-title":"Cancers"},{"issue":"1","key":"4385_CR95","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J translational Med. 2023;21(1):449.","journal-title":"J translational Med"},{"issue":"7","key":"4385_CR96","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/cancers17071098","volume":"17","author":"M El Hage","year":"2025","unstructured":"El Hage M, Su Z, Linnebacher M. Addressing challenges in targeted therapy for metastatic colorectal cancer. Cancers. 2025;17(7):1098.","journal-title":"Cancers"},{"key":"4385_CR97","doi-asserted-by":"publisher","first-page":"978195","DOI":"10.3389\/fimmu.2022.978195","volume":"13","author":"B Ghazi","year":"2022","unstructured":"Ghazi B, et al. CAR T-cells for colorectal cancer immunotherapy: Ready to go? Front Immunol. 2022;13:978195.","journal-title":"Front Immunol"},{"issue":"1","key":"4385_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12(1):14.","journal-title":"Exp Hematol Oncol"},{"key":"4385_CR99","doi-asserted-by":"publisher","unstructured":"Halford MM, He MY, Amin N, et al. An endothelial cell competition assay for determinants of the response to targeted anti-angiogenics. Growth Factors. 2025;43(2):127-153. https:\/\/doi.org\/10.1080\/08977194.2025.2516463.","DOI":"10.1080\/08977194.2025.2516463"},{"issue":"3","key":"4385_CR100","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2025.01.029","volume":"33","author":"A Senevirathne","year":"2025","unstructured":"Senevirathne A, et al. Transforming bacterial pathogens into wonder tools in cancer immunotherapy. Molecular Therapy. 2025;33(3):866\u201382.","journal-title":"Molecular Therapy"},{"issue":"3","key":"4385_CR101","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10620-024-08774-2","volume":"70","author":"N Fatemi","year":"2025","unstructured":"Fatemi N, et al. Emerging frontiers in colorectal cancer therapy: from targeted molecules to immunomodulatory breakthroughs and cell-based approaches. Digestive Diseases and Sciences. 2025;70(3):919\u201342.","journal-title":"Digestive Diseases and Sciences"},{"issue":"2","key":"4385_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020412","volume":"16","author":"N Saoudi Gonz\u00e1lez","year":"2024","unstructured":"Saoudi Gonz\u00e1lez N, et al. Cetuximab as a key partner in personalized targeted therapy for metastatic colorectal cancer. Cancers. 2024;16(2):412.","journal-title":"Cancers"},{"issue":"1","key":"4385_CR103","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imr.12393","volume":"270","author":"M Klinger","year":"2016","unstructured":"Klinger M, et al. Harnessing T cells to fight cancer with BiTE\u00ae antibody constructs\u2013past developments and future directions. Immunological reviews. 2016;270(1):193\u2013208.","journal-title":"Immunological reviews"},{"issue":"8","key":"4385_CR104","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/14712598.2022.2072209","volume":"22","author":"RP Chen","year":"2022","unstructured":"Chen RP, et al. Bispecific antibodies for immune cell retargeting against cancer. Expert Opinion on Biological Therapy. 2022;22(8):965\u201382.","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"6","key":"4385_CR105","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1007\/s10637-020-00955-w","volume":"38","author":"Z-W Han","year":"2020","unstructured":"Han Z-W, et al. The old CEACAMs find their new role in tumor immunotherapy. Investigational New Drugs. 2020;38(6):1888\u201398.","journal-title":"Investigational New Drugs"},{"key":"4385_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1048166","volume":"12","author":"B Doleschal","year":"2022","unstructured":"Doleschal B, Petzer A, Rumpold H. Current concepts of anti-EGFR targeting in metastatic colorectal cancer. Frontiers in Oncology. 2022;12:1048166.","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"4385_CR107","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40259-017-0223-8","volume":"31","author":"X Yu","year":"2017","unstructured":"Yu X, et al. Improving antibody-based cancer therapeutics through glycan engineering. BioDrugs. 2017;31(3):151\u201366.","journal-title":"BioDrugs"},{"issue":"1","key":"4385_CR108","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","volume":"40","author":"J Zhou","year":"2021","unstructured":"Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40(1):328.","journal-title":"J Exp Clin Cancer Res"},{"key":"4385_CR109","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fonc.2019.00849","volume":"9","author":"J Garc\u00eda-Foncillas","year":"2019","unstructured":"Garc\u00eda-Foncillas J, et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front Oncol. 2019;9:849.","journal-title":"Front Oncol"},{"key":"4385_CR110","doi-asserted-by":"publisher","unstructured":"Holubec L, Polivka J Jr, Safanda M, Karas M, Liska V. The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment. Anticancer Res. 2016;36(9):4421-4426. https:\/\/doi.org\/10.21873\/anticanres.10985.","DOI":"10.21873\/anticanres.10985"},{"issue":"6","key":"4385_CR111","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nm.4078","volume":"22","author":"C Pozzi","year":"2016","unstructured":"Pozzi C, et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med. 2016;22(6):624\u201331.","journal-title":"Nat Med"},{"key":"4385_CR112","doi-asserted-by":"crossref","unstructured":"Srivastava S, et al. Precision Medicine in Colorectal Cancer: Targeted Therapies and Biomarker Insights. Current Cancer Drug Targets; 2025.","DOI":"10.2174\/0115680096338273241224061021"},{"issue":"3","key":"4385_CR113","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"4385_CR114","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-019-0575-3","volume":"7","author":"R Gonzalez-Exposito","year":"2019","unstructured":"Gonzalez-Exposito R, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019;7(1):101.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4385_CR115","doi-asserted-by":"publisher","first-page":"2322562","DOI":"10.1080\/19420862.2024.2322562","volume":"16","author":"G Frey","year":"2024","unstructured":"Frey G, et al. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy. MAbs. 2024;16(1):2322562.","journal-title":"MAbs"},{"issue":"8","key":"4385_CR116","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","volume":"22","author":"K Peng","year":"2025","unstructured":"Peng K, et al. Eliciting antitumor immunity via therapeutic cancer vaccines. Cell Mol Immunol. 2025;22(8):840\u201368.","journal-title":"Cell Mol Immunol"},{"key":"4385_CR117","doi-asserted-by":"crossref","unstructured":"Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol. 2010;2010:596432. https:\/\/pubmed.ncbi.nlm.nih.gov\/20706612\/.","DOI":"10.1155\/2010\/596432"},{"key":"4385_CR118","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.medidd.2022.100144","volume":"16","author":"Z Wu","year":"2022","unstructured":"Wu Z, Yang M, Cao Y. Tumor antigens and vaccines in colorectal cancer. Med Drug Discovery. 2022;16:100144.","journal-title":"Med Drug Discovery"},{"issue":"16","key":"4385_CR119","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.3390\/cancers14163972","volume":"14","author":"C Peterson","year":"2022","unstructured":"Peterson C, Denlinger N, Yang Y. Recent advances and challenges in cancer immunotherapy. Cancers. 2022;14(16):3972.","journal-title":"Cancers"},{"issue":"22","key":"4385_CR120","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.7150\/jca.62123","volume":"12","author":"L Liu","year":"2021","unstructured":"Liu L, et al. Synergistic killing effects of PD-L1-CAR T cells and colorectal cancer stem cell-dendritic cell vaccine-sensitized T cells in ALDH1-positive colorectal cancer stem cells. J Cancer. 2021;12(22):6629.","journal-title":"J Cancer"},{"key":"4385_CR121","doi-asserted-by":"publisher","first-page":"112037","DOI":"10.1016\/j.intimp.2024.112037","volume":"132","author":"J Song","year":"2024","unstructured":"Song J, et al. The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy. Int Immunopharmacol. 2024;132:112037.","journal-title":"Int Immunopharmacol"},{"key":"4385_CR122","doi-asserted-by":"publisher","unstructured":"Zhou P, Zhang W, Liao Y, et al. Colorectal cancer: the immune microenvironment and the gut microbiota - new perspectives, challenges, and opportunities. Int J Surg. 2025;111(8):5363-5386. https:\/\/doi.org\/10.1097\/JS9.0000000000002573.","DOI":"10.1097\/JS9.0000000000002573"},{"issue":"2","key":"4385_CR123","doi-asserted-by":"publisher","first-page":"189281","DOI":"10.1016\/j.bbcan.2025.189281","volume":"1880","author":"F Ghorbaninezhad","year":"2025","unstructured":"Ghorbaninezhad F, et al. The tumor microenvironment and dendritic cells: Developers of pioneering strategies in colorectal cancer immunotherapy? Biochim Biophys Acta Rev Cancer. 2025;1880(2):189281.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"4385_CR124","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","volume":"24","author":"Z Yan","year":"2024","unstructured":"Yan Z, et al. Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments. Cancer Cell Int. 2024;24(1):242.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"4385_CR125","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/imm.13785","volume":"173","author":"L Cai","year":"2024","unstructured":"Cai L, Chen A, Tang D. A new strategy for immunotherapy of microsatellite-stable (MSS)\u2010type advanced colorectal cancer: multi\u2010pathway combination therapy with PD\u20101\/PD\u2010L1 inhibitors. Immunology. 2024;173(2):209\u201326.","journal-title":"Immunology"},{"key":"4385_CR126","doi-asserted-by":"publisher","first-page":"1018767","DOI":"10.3389\/fonc.2022.1018767","volume":"12","author":"T Augustine","year":"2022","unstructured":"Augustine T, et al. Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer. Front Oncol. 2022;12:1018767.","journal-title":"Front Oncol"},{"issue":"5","key":"4385_CR127","doi-asserted-by":"publisher","first-page":"e010570","DOI":"10.1136\/jitc-2024-010570","volume":"13","author":"V Mullins-Dansereau","year":"2025","unstructured":"Mullins-Dansereau V, et al. Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities. J Immunother Cancer. 2025;13(5):e010570.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4385_CR128","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2174\/0115680096273465231201115839","volume":"24","author":"R Karbalaee","year":"2024","unstructured":"Karbalaee R, et al. The Effects of Mesenchymal Stem Cells Loaded with Oncolytic Coxsackievirus A21 on Mouse Models of Colorectal Cancer. Curr Cancer Drug Targets. 2024;24(9):967\u201374.","journal-title":"Curr Cancer Drug Targets"},{"key":"4385_CR129","unstructured":"Jittprasong C. Mesenchymal stem cells as carrier cells to enable effective intratumoral delivery of oncolytic virus for oncolytic virotherapy: a systematic review. arXiv preprint arXiv:2204.01238, 2022."},{"issue":"2","key":"4385_CR130","doi-asserted-by":"publisher","first-page":"e005640","DOI":"10.1136\/jitc-2022-005640","volume":"11","author":"C Monge","year":"2023","unstructured":"Monge C, et al. Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. J Immunother Cancer. 2023;11(2):e005640.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4385_CR131","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41417-024-00807-2","volume":"31","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient. Cancer Gene Therapy. 2024;31(9):1412\u201326.","journal-title":"Cancer Gene Therapy"},{"key":"4385_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215937","volume":"550","author":"SJ Li","year":"2022","unstructured":"Li SJ, Sun ZJ. Fueling immune checkpoint blockade with oncolytic viruses: current paradigms and challenges ahead. Cancer Lett. 2022;550:215937.","journal-title":"Cancer Lett"},{"issue":"1","key":"4385_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-024-00304-0","volume":"16","author":"S Li","year":"2024","unstructured":"Li S, et al. m(1)A inhibition fuels oncolytic virus-elicited antitumor immunity via downregulating MYC\/PD-L1 signaling. Int J Oral Sci. 2024;16(1):36.","journal-title":"Int J Oral Sci"},{"issue":"1","key":"4385_CR134","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2333790","volume":"16","author":"N Wang","year":"2024","unstructured":"Wang N, et al. Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. Gut Microbes. 2024;16(1):2333790.","journal-title":"Gut Microbes"},{"issue":"1","key":"4385_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00786-8","volume":"11","author":"W Lei","year":"2025","unstructured":"Lei W, et al. Gut microbiota shapes cancer immunotherapy responses. npj Biofilms and Microbiomes. 2025;11(1):143.","journal-title":"npj Biofilms and Microbiomes"},{"issue":"1","key":"4385_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03968-y","volume":"25","author":"M Deng","year":"2025","unstructured":"Deng M, et al. The current status and prospects of gut microbiota combined with PD-1\/PD-L1 inhibitors in the treatment of colorectal cancer: a review. BMC Gastroenterol. 2025;25(1):380.","journal-title":"BMC Gastroenterol"},{"key":"4385_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874922","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, et al. Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer. Frontiers in Immunology. 2022;13:874922.","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"4385_CR138","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/1040841X.2022.2109405","volume":"49","author":"SSW Effendi","year":"2023","unstructured":"Effendi SSW, Ng I-S. Prospective and challenges of live bacterial therapeutics from a superhero Escherichia coli Nissle 1917. Critical Reviews in Microbiology. 2023;49(5):611\u201327.","journal-title":"Critical Reviews in Microbiology"},{"key":"4385_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2023.103061","volume":"85","author":"JG Zalatan","year":"2024","unstructured":"Zalatan JG, Petrini L, Geiger R. Engineering bacteria for cancer immunotherapy. Curr Opin Biotechnol. 2024;85:103061.","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"4385_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00442-x","volume":"12","author":"M Zhang","year":"2023","unstructured":"Zhang M, Liu J, Xia Q. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. Exp Hematol Oncol. 2023;12(1):84.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"4385_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03968-y","volume":"25","author":"M Deng","year":"2025","unstructured":"Deng M, et al. The current status and prospects of gut microbiota combined with PD-1\/PD-L1 inhibitors in the treatment of colorectal cancer: a review. BMC Gastroenterol. 2025;25(1):380.","journal-title":"BMC Gastroenterol"},{"key":"4385_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433989","volume":"15","author":"S Rokade","year":"2024","unstructured":"Rokade S, et al. IL-2 based cancer immunotherapies: an evolving paradigm. Front Immunol. 2024;15:1433989.","journal-title":"Front Immunol"},{"issue":"1","key":"4385_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84693-6","volume":"15","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Luo R, Li E. Combined delivery of IL12 and an IL18 mutant without IL18BP-binding activity by an adenoviral vector enhances tumor specific immunity. Sci Rep. 2025;15(1):3563.","journal-title":"Sci Rep"},{"key":"4385_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1227833","volume":"14","author":"S Chakraborty","year":"2023","unstructured":"Chakraborty S, et al. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy. Front Immunol. 2023;14:1227833.","journal-title":"Front Immunol"},{"issue":"5","key":"4385_CR145","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.apsb.2024.02.006","volume":"14","author":"Z Li","year":"2024","unstructured":"Li Z, et al. Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy. Acta Pharm Sin B. 2024;14(5):2194\u2013209.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"4385_CR146","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41423-021-00735-3","volume":"19","author":"W Du","year":"2022","unstructured":"Du W, et al. IFN\u03b3 signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol. 2022;19(1):23\u201332.","journal-title":"Cell Mol Immunol"},{"key":"4385_CR147","unstructured":"Palmeri M et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. (2059\u20137029 (Electronic))."},{"key":"4385_CR148","unstructured":"Fabrizio DA et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. (2078\u20136891 (Print))."},{"key":"4385_CR149","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2031965","author":"B Rousseau","year":"2021","unstructured":"Rousseau B, et al. The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. New England Journal of Medicine. 2021. https:\/\/doi.org\/10.1056\/nejmc2031965.","journal-title":"New England Journal of Medicine"},{"key":"4385_CR150","doi-asserted-by":"publisher","unstructured":"Hamarsheh S-O, et al. Immune modulatory effects of oncogenic KRAS in cancer. Nature Communications. 2041(1). https:\/\/doi.org\/10.1038\/s41467-020-19288-6.","DOI":"10.1038\/s41467-020-19288-6"},{"key":"4385_CR151","doi-asserted-by":"publisher","unstructured":"Kopetz S, et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology. 2017. https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.3505.","DOI":"10.1200\/jco.2017.35.15_suppl.3505"},{"key":"4385_CR152","doi-asserted-by":"crossref","unstructured":"Park R et al. Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability\/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis. 2021, Wolters Kluwer Health.","DOI":"10.1200\/JCO.2021.39.15_suppl.3557"},{"key":"4385_CR153","unstructured":"Morris VK, et al. Phase I\/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF V600E metastatic colorectal cancer. American Society of Clinical Oncology; 2022."},{"key":"4385_CR154","doi-asserted-by":"publisher","unstructured":"Liu J, et al. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients. Journal of Translational Medicine. 2021(1). https:\/\/doi.org\/10.1186\/s12967-020-02638-9.","DOI":"10.1186\/s12967-020-02638-9"},{"key":"4385_CR155","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw588.003","author":"N Chen","year":"2016","unstructured":"Chen N, et al. 397PD KRAS mutation-induced upregulation of PD-L1 mediates immune escape in lung adenocarcinoma. Annals of Oncology. 2016. https:\/\/doi.org\/10.1093\/annonc\/mdw588.003.","journal-title":"Annals of Oncology"},{"key":"4385_CR156","doi-asserted-by":"publisher","unstructured":"Dong ZY, et al. MA15.10 Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Journal of Thoracic Oncology. 2017(1). https:\/\/doi.org\/10.1016\/j.jtho.2016.11.504.","DOI":"10.1016\/j.jtho.2016.11.504"},{"key":"4385_CR157","unstructured":"Yang LA-O, Xue R, Pan C. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis. (1178\u20136930 (Print))."},{"key":"4385_CR158","doi-asserted-by":"publisher","unstructured":"Alexander PG, McMillan DC, Park JH. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. Crit Rev Oncol Hematol. 2021;157:103147. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103147.","DOI":"10.1016\/j.critrevonc.2020.103147"},{"key":"4385_CR159","doi-asserted-by":"publisher","unstructured":"Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016 Aug 12;9:5023-39. PMID: 27574444; PMCID: PMC4990391. https:\/\/doi.org\/10.2147\/OTT.S105862.","DOI":"10.2147\/OTT.S105862"},{"key":"4385_CR160","doi-asserted-by":"publisher","unstructured":"Krishna S, Lowery FJ, Copeland AR, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020;370(6522):1328-1334. https:\/\/doi.org\/10.1126\/science.abb9847.","DOI":"10.1126\/science.abb9847"},{"key":"4385_CR161","unstructured":"Chen YP et al. Genomic Analysis of Tumor Microenvironment Immune Types across 14. Solid Cancer Types: Immunotherapeutic Implications. (1838\u20137640 (Electronic))."},{"key":"4385_CR162","doi-asserted-by":"publisher","unstructured":"Pai CS, Huang JT, Lu X, et al. Clonal Deletion of Tumor-Specific T Cells by Interferon-\u03b3 Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019;50(2):477-492.e8. https:\/\/doi.org\/10.1016\/j.immuni.2019.01.006.","DOI":"10.1016\/j.immuni.2019.01.006"},{"key":"4385_CR163","unstructured":"Peng D et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. (1476\u20134687 (Electronic))."},{"issue":"1","key":"4385_CR164","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41423-021-00735-3","volume":"19","author":"W Du","year":"2022","unstructured":"Du W, et al. IFN\u03b3 signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol. 2022;19(1):23\u201332.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"4385_CR165","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.3390\/ijms27052251","volume":"27","author":"MC Pavalean","year":"2026","unstructured":"Pavalean MC, et al. Screening, Prognostic, and Predictive Molecular Tools for Colorectal Cancer: Recent Advances in the Classical Background. Int J Mol Sci. 2026;27(5):2251.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4385_CR166","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4132\/jptm.2020.05.15","volume":"54","author":"JM Bae","year":"2020","unstructured":"Bae JM, et al. Immune landscape and biomarkers for immuno-oncology in colorectal cancers. J Pathol Translational Med. 2020;54(5):351\u201360.","journal-title":"J Pathol Translational Med"},{"key":"4385_CR167","doi-asserted-by":"publisher","first-page":"1732079","DOI":"10.3389\/fimmu.2026.1732079","volume":"17","author":"X Wang","year":"2026","unstructured":"Wang X, et al. Artificial intelligence\u2013enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation. Front Immunol. 2026;17:1732079.","journal-title":"Front Immunol"},{"key":"4385_CR168","unstructured":"Gong J et al. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation. (1540\u2009\u2013\u20091413 (Electronic))."},{"key":"4385_CR169","doi-asserted-by":"publisher","unstructured":"Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019;5(10):1504-1506. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2963.","DOI":"10.1001\/jamaoncol.2019.2963"},{"key":"4385_CR170","doi-asserted-by":"crossref","unstructured":"Shang Z et al. October 31,., DNA damage repair molecular subtype derived immune signature applicable for the prognosis and immunotherapy response prediction in colon cancer. Translational Cancer Research; Vol 12, No 10 (2023): Translational Cancer Research, 2023.","DOI":"10.21037\/tcr-23-747"},{"key":"4385_CR171","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.757","author":"G Wu","year":"2021","unstructured":"Wu G. Therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and influencing factors. Indian J Pharm Sci. 2021. https:\/\/doi.org\/10.36468\/pharmaceutical-sciences.757.","journal-title":"Indian J Pharm Sci"},{"key":"4385_CR172","doi-asserted-by":"publisher","unstructured":"Arai H, Elliott A, Millstein J, et al. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene. 2022;41(2):260-267. https:\/\/doi.org\/10.1038\/s41388-021-02074-z.","DOI":"10.1038\/s41388-021-02074-z"},{"key":"4385_CR173","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.3604","author":"M Nusrat","year":"2019","unstructured":"Nusrat M, et al. Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). J Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.3604.","journal-title":"J Clin Oncol"},{"key":"4385_CR174","doi-asserted-by":"publisher","unstructured":"Elez E, Ros J, Fern\u00e1ndez J, et al. RNF43 mutations predict response to anti-BRAF\/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat Med. 2022;28(10):2162-2170. https:\/\/doi.org\/10.1038\/s41591-022-01976-z.","DOI":"10.1038\/s41591-022-01976-z"},{"key":"4385_CR175","doi-asserted-by":"publisher","first-page":"110703","DOI":"10.1016\/j.intimp.2023.110703","volume":"123","author":"H Ouyang","year":"2023","unstructured":"Ouyang H, et al. Baseline and early changes in the neutrophil\u2013lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy. Int Immunopharmacol. 2023;123:110703.","journal-title":"Int Immunopharmacol"},{"key":"4385_CR176","doi-asserted-by":"publisher","unstructured":"Bortolomeazzi M, Keddar MR, Montorsi L, et al. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. Gastroenterology. 2021;161(4):1179-1193. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.064.","DOI":"10.1053\/j.gastro.2021.06.064"},{"key":"4385_CR177","doi-asserted-by":"publisher","unstructured":"Gao J, Shi LZ, Zhao H, et al. Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397-404.e9. https:\/\/doi.org\/10.1016\/j.cell.2016.08.069.","DOI":"10.1016\/j.cell.2016.08.069"},{"issue":"5","key":"4385_CR178","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3892\/ol.2020.12119","volume":"20","author":"W Yuan","year":"2020","unstructured":"Yuan W, et al. Prognostic value of immune scores in the microenvironment of colorectal cancer. Oncol Lett. 2020;20(5):256.","journal-title":"Oncol Lett"},{"key":"4385_CR179","unstructured":"Goc J et al. Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. (1097\u20134172 (Electronic))."},{"issue":"4_suppl","key":"4385_CR180","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2022.40.4_suppl.136","volume":"40","author":"JY Zhang","year":"2022","unstructured":"Zhang JY, et al. Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer. J Clin Oncol. 2022;40(4_suppl):136\u2013136.","journal-title":"J Clin Oncol"},{"key":"4385_CR181","doi-asserted-by":"publisher","unstructured":"Liu Z, Lu T, Wang Y, et al. Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer. J Cell Mol Med. 2021;25(14):6874-6886. https:\/\/doi.org\/10.1111\/jcmm.16696.","DOI":"10.1111\/jcmm.16696"},{"issue":"8","key":"4385_CR182","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2025.1646","volume":"11","author":"J Ta\u00efeb","year":"2025","unstructured":"Ta\u00efeb J, et al. Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical Trial. JAMA Oncol. 2025;11(8):874\u201382.","journal-title":"JAMA Oncol"},{"key":"4385_CR183","doi-asserted-by":"publisher","unstructured":"Kagamu H, Kitano S, Yamaguchi O, et al. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunol Res. 2020;8(3):334-344. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0574.","DOI":"10.1158\/2326-6066.CIR-19-0574"},{"issue":"12","key":"4385_CR184","doi-asserted-by":"publisher","first-page":"e010094","DOI":"10.1136\/jitc-2024-010094","volume":"12","author":"LX Ma","year":"2024","unstructured":"Ma LX, et al. Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial. J Immunother Cancer. 2024;12(12):e010094.","journal-title":"J Immunother Cancer"},{"key":"4385_CR185","unstructured":"Gao Y et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. (2059\u20133635 (Electronic))."},{"key":"4385_CR186","unstructured":"Sivan A et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. (1095\u20139203 (Electronic))."},{"key":"4385_CR187","doi-asserted-by":"publisher","unstructured":"Peng Z, Cheng S, Kou Y, et al. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1\/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunol Res. 2020;8(10):1251-1261. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-1014.","DOI":"10.1158\/2326-6066.CIR-19-1014"},{"key":"4385_CR188","doi-asserted-by":"publisher","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-97. https:\/\/doi.org\/10.1126\/science.aan3706.","DOI":"10.1126\/science.aan3706"},{"key":"4385_CR189","doi-asserted-by":"crossref","unstructured":"Aindelis G et al. Immune Responses Raised in an Experimental Colon Carcinoma Model Following Oral Administration of Lactobacillus casei. LID\u2009\u2013\u200910.3390\/cancers12020368 [doi] LID\u2009\u2013\u2009368. (2072\u20136694 (Print)).","DOI":"10.3390\/cancers12020368"},{"key":"4385_CR190","unstructured":"Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. (1557\u20133265 (Electronic))."},{"key":"4385_CR191","unstructured":"Shang X et al. Identification of MDM4 as a Prognostic Biomarker and a Target for Therapeutics in Colorectal Cancer. LID\u2009\u2013\u200910.1002\/bab.70002 [doi]. (1470\u20138744 (Electronic))."},{"issue":"1","key":"4385_CR192","doi-asserted-by":"publisher","first-page":"13665","DOI":"10.1038\/ncomms13665","volume":"7","author":"BO Van Emburgh","year":"2016","unstructured":"Van Emburgh BO, et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016;7(1):13665.","journal-title":"Nat Commun"},{"key":"4385_CR193","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.carbpol.2018.06.114","volume":"199","author":"H Hamedi","year":"2018","unstructured":"Hamedi H, et al. Chitosan based hydrogels and their applications for drug delivery in wound dressings: A review. Carbohydr Polym. 2018;199:445\u201360.","journal-title":"Carbohydr Polym"},{"key":"4385_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113153","volume":"142","author":"X Wan","year":"2024","unstructured":"Wan X, Li Z, Zhou L. c-MET is an important marker for acid-driven metastasis and anti-immune in colorectal cancer. International Immunopharmacology. 2024;142:113153.","journal-title":"International Immunopharmacology"},{"key":"4385_CR195","doi-asserted-by":"publisher","unstructured":"Lee YH, Yang CF, Liou YF, Huang KC, Chao KSC, Chiang SF. Prognostic Significance of STK11\/LKB1 Expression and Its Role in the Tumor Microenvironment of Colorectal Adenocarcinoma. In Vivo. 2025;39(2):691-701. https:\/\/doi.org\/10.21873\/invivo.13873.","DOI":"10.21873\/invivo.13873"},{"key":"4385_CR196","doi-asserted-by":"publisher","unstructured":"Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97(8):1139-1145. https:\/\/doi.org\/10.1038\/sj.bjc.6604009.","DOI":"10.1038\/sj.bjc.6604009"},{"key":"4385_CR197","unstructured":"Middha S et al. Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. LID\u2009\u2013\u200910.1200\/PO.18.00321 [doi] LID - PO.18.00321. (2473\u20134284 (Print))."},{"key":"4385_CR198","unstructured":"Shin DS et al. Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations. (2159\u20138290 (Electronic))."},{"issue":"6","key":"4385_CR199","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1158\/1541-7786.MCR-19-1201","volume":"18","author":"A Georgiou","year":"2020","unstructured":"Georgiou A, et al. Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS\/NRAS\/BRAFV600-Wild-Type Colorectal Cancer. Mol Cancer Res. 2020;18(6):835\u201346.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"4385_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166353","volume":"1868","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, et al. DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK\/ERK activation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2022;1868(4):166353.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"4385_CR201","doi-asserted-by":"crossref","unstructured":"Sui QA-OX et al. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8\u2009+\u2009T cells in deficient mismatch repair colorectal cancer. LID\u2009\u2013\u200910.1136\/jitc-2020-001498 [doi] LID - e001498. (2051\u2009\u2013\u20091426 (Electronic)).","DOI":"10.1136\/jitc-2020-001498"},{"issue":"1","key":"4385_CR202","doi-asserted-by":"publisher","first-page":"e001895","DOI":"10.1136\/jitc-2020-001895","volume":"9","author":"C Liu","year":"2021","unstructured":"Liu C, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9(1):e001895.","journal-title":"J Immunother Cancer"},{"key":"4385_CR203","unstructured":"Dong X et al. Upregulation of LAGE3 correlates with prognosis and immune infiltrates in colorectal cancer: A bioinformatic analysis. (1878\u2009\u2013\u20091705 (Electronic))."},{"key":"4385_CR204","unstructured":"Van Wilpe S et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. (2162\u20134011 (Print))."},{"key":"4385_CR205","unstructured":"Calu V et al. Key biomarkers within the colorectal cancer related inflammatory microenvironment. (2045\u20132322 (Electronic))."},{"key":"4385_CR206","doi-asserted-by":"publisher","unstructured":"Sorrentino C, D'Antonio L, Fieni C, Ciummo SL, Di Carlo E. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. Front Immunol. 2021;12:778329. https:\/\/doi.org\/10.3389\/fimmu.2021.778329.","DOI":"10.3389\/fimmu.2021.778329"},{"key":"4385_CR207","doi-asserted-by":"crossref","unstructured":"Tian S, et al. Global Pattern of CD8\u2009+\u2009T-Cell Infiltration and Exhaustion in Colorectal Cancer Predicts Cancer Immunotherapy Response. Frontiers in Pharmacology; 2021. pp. 12\u20132021.","DOI":"10.3389\/fphar.2021.715721"},{"issue":"1","key":"4385_CR208","doi-asserted-by":"publisher","first-page":"16550","DOI":"10.1038\/s41598-025-01185-x","volume":"15","author":"D Zou","year":"2025","unstructured":"Zou D, et al. Development and validation of a cancer-associated fibroblast gene signature-based model for predicting immunotherapy response in colon cancer. Sci Rep. 2025;15(1):16550.","journal-title":"Sci Rep"},{"key":"4385_CR209","doi-asserted-by":"crossref","unstructured":"Thoma OM, Neurath MF, Waldner MJ. T Cell Aging in Patients with Colorectal Cancer-What Do We Know So Far? LID\u2009\u2013\u200910.3390\/cancers13246227 [doi] LID\u2009\u2013\u20096227. (2072\u20136694 (Print)).","DOI":"10.3390\/cancers13246227"},{"key":"4385_CR210","unstructured":"Tauriello DVF et al. TGF\u03b2 drives immune evasion genetically reconstituted colon cancer metastasis (1476\u20134687 (Electronic))."},{"key":"4385_CR211","unstructured":"Kim, C.A.-O., et al., VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. LID - eaay0555 [pii] LID - 10.1126\/sciimmunol.aay0555 [doi]. (2470-9468 (Electronic))."},{"key":"4385_CR212","doi-asserted-by":"crossref","unstructured":"Fuc\u00e0 GA-O et al. Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers. LID\u2009\u2013\u200910.1136\/jitc-2021-004001 [doi] LID - e004001. (2051\u2009\u2013\u20091426 (Electronic)).","DOI":"10.1136\/jitc-2021-004001"},{"issue":"10","key":"4385_CR213","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","volume":"30","author":"A Elkrief","year":"2019","unstructured":"Elkrief A, et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30(10):1572\u20139.","journal-title":"Ann Oncol"},{"issue":"2","key":"4385_CR214","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.757","volume":"9","author":"E Chatelut","year":"2021","unstructured":"Chatelut E, et al. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacol Res Perspect. 2021;9(2):e00757.","journal-title":"Pharmacol Res Perspect"},{"key":"4385_CR215","unstructured":"Patel MR et al. A phase 2 trial of trifluridine\/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer. (2045\u20137634 (Electronic))."},{"key":"4385_CR216","doi-asserted-by":"crossref","unstructured":"Segal NH et al. Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients. 2016, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2016.34.15_suppl.3539"},{"key":"4385_CR217","doi-asserted-by":"crossref","unstructured":"Liao Y et al. Advances in radiotherapy enhancing the efficacy of immune checkpoint inhibitors in malignant. Front Oncol, 2025. Volume 15\u20132025.","DOI":"10.3389\/fonc.2025.1611036"},{"key":"4385_CR218","doi-asserted-by":"publisher","unstructured":"Salama AKS, Wang V, Macrae ER, et al. Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. JCO Precis Oncol. 2026;10:e2500338. https:\/\/doi.org\/10.1200\/PO-25-00338.","DOI":"10.1200\/PO-25-00338"},{"key":"4385_CR219","doi-asserted-by":"crossref","unstructured":"Cassier PA, et al. MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). American Society of Clinical Oncology; 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.2579"},{"key":"4385_CR220","unstructured":"Al-Shamma SA et al. Targeting aldehyde dehydrogenase enzymes in combination with chemotherapy and immunotherapy: An approach to tackle resistance in cancer cells. (1879\u2009\u2013\u20090631 (Electronic))."},{"key":"4385_CR221","doi-asserted-by":"crossref","unstructured":"Loree JM, et al. Impact of consensus molecular subtyping (CMS) on survival in the CO. 26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC). American Society of Clinical Oncology; 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.3551"},{"key":"4385_CR222","doi-asserted-by":"crossref","unstructured":"Satapathy BP et al. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review. Front Immunol, 2024. Volume 15\u20132024.","DOI":"10.3389\/fimmu.2024.1389971"},{"key":"4385_CR223","unstructured":"Chen CY et al. Oncolytic virus and PD-1\/PD-L1 blockade combination therapy. (2253\u2009\u2013\u20091572 (Print))."},{"key":"4385_CR224","unstructured":"Randomized A., Open-Label, Phase 2 Study of a Patient-Specific Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer With Minimal Residual Disease Following Surgical Resection and Standard Adjuvant Chemotherapy. 2022."},{"key":"4385_CR225","unstructured":"Phase A. I, Two-arm, Open-label, Single-center, Dose-escalation Study to Evaluate the Safety, Tolerability and Recommended Dose and Delivery Mode of the Pan-immunotherapy in Subjects With Unresectable\/ Metastatic Solid Tumors or Lymphomas. 2019."},{"issue":"1","key":"4385_CR226","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"key":"4385_CR227","doi-asserted-by":"crossref","unstructured":"Bassan D et al. HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity. LID\u2009\u2013\u200910.1136\/jitc-2023-007426 [doi] LID - e007426. (2051\u2009\u2013\u20091426 (Electronic)).","DOI":"10.1136\/jitc-2023-007426"},{"key":"4385_CR228","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1554256","author":"L Qin","year":"2025","unstructured":"Qin L, et al. Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1554256.","journal-title":"Front Immunol"},{"key":"4385_CR229","doi-asserted-by":"publisher","unstructured":"Xiang J, Wang J, Xiao H, et al. Targeting tumor-associated macrophages in colon cancer: mechanisms and therapeutic strategies. Front Immunol. 2025;16:1573917. Published 2025 Mar 21. https:\/\/doi.org\/10.3389\/fimmu.2025.1573917.","DOI":"10.3389\/fimmu.2025.1573917"},{"issue":"19","key":"4385_CR230","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"4385_CR231","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s43856-025-00852-4","volume":"5","author":"G Patelli","year":"2025","unstructured":"Patelli G, et al. Clinical utility and future perspectives of liquid biopsy in colorectal cancer. Commun Med. 2025;5(1):137.","journal-title":"Commun Med"},{"key":"4385_CR232","unstructured":"In-Situ Cancer Vaccine: Phase IIA, Open-Label Study to Assess the Safety of AlloStim\u00ae Immunotherapy Alone and in Combination With Cryoablation as Third Line Therapy for Metastatic Colorectal Cancer. 2015."},{"key":"4385_CR233","volume-title":"Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer","author":"Safety","year":"2017","unstructured":"Safety. Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer, C. Mayo, Editors. 2017."},{"key":"4385_CR234","doi-asserted-by":"publisher","unstructured":". Lenz HJ, Parikh A, Spigel DR, et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024;12(3):e008409. https:\/\/doi.org\/10.1136\/jitc-2023-008409.","DOI":"10.1136\/jitc-2023-008409"},{"key":"4385_CR235","volume-title":"Study of Pixatimod (PG545) in Combination With Nivolumab in PD-1 Relapsed\/Refractory Metastatic Melanoma and NSCLC and Pixatimod (PG545) in Combination With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)","author":"IIAB Phase","year":"2021","unstructured":"Phase IIAB. Study of Pixatimod (PG545) in Combination With Nivolumab in PD-1 Relapsed\/Refractory Metastatic Melanoma and NSCLC and Pixatimod (PG545) in Combination With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC), T. Aculeus, Editor. 2021."},{"key":"4385_CR236","doi-asserted-by":"publisher","unstructured":"Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013;258(6):879-886. https:\/\/doi.org\/10.1097\/SLA.0b013e318292919e.","DOI":"10.1097\/SLA.0b013e318292919e"},{"key":"4385_CR237","volume-title":"Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab","author":"A Phase","year":"2018","unstructured":"Phase A. Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab, S. Bristol-Myers, Editor. 2018."},{"key":"4385_CR238","unstructured":"Phase Ib A. \/II Trial of M7824 in Solid Tumors With Microsatellite Instability With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer in Combination With Radiation, or in Colorectal Cancer Patients With Detectable Circulating Tumor DNA Following Definitive Therapy, I. National Cancer, Editor. 2018."},{"key":"4385_CR239","unstructured":"Phase A. I\/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer, I. Oncovir, S. Merck, and L.L.C. Dohme, Editors. 2016."},{"key":"4385_CR240","unstructured":"Phase A. and S. Bristol-Myers, Editors. 2018."},{"key":"4385_CR241","unstructured":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers. 2020."},{"key":"4385_CR242","unstructured":"A Phase 2 Study of GVAX Colon Vaccine (With Cyclophosphamide) and Pembrolizumab in Patients With Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer, S. Merck and L.L.C. Dohme, Editors. 2016."},{"key":"4385_CR243","doi-asserted-by":"publisher","unstructured":"Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2013;6(1):18-26. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-12-0275.","DOI":"10.1158\/1940-6207.CAPR-12-0275"},{"key":"4385_CR244","unstructured":"Phase A. I\/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer. 2017."},{"key":"4385_CR245","unstructured":"ClinicalTrials.gov. Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma. National Library of Medicine. ClinicalTrials.gov identifier: NCT01394939"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04385-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:02:23Z","timestamp":1787544143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04385-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":245,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4385"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04385-1","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"294"}}